Robenidine as an anticoccidial agent alone (in doses of 50 and 100 mg/kg) or in association with two other antiprotozoal compounds--pyrimethamine and sulfadoxine (in doses of 2.5 and 250 mg/kg, respectively) were tested in the treatment of chronically infected mice with an avirulent cyst-forming HF strain of Toxoplasma gondii. The efficacy of the used drugs was evaluated by the cysts number in the brains of treated mice versus control group, antibody level and viability of survived cysts by the consecutive infection of mice. According to these criteria none of the tested drugs alone or combined exhibited to be able to produce an effective cure of cyst-stage of toxoplasmosis in experimental mice.

• MeSH
• Guanidines therapeutic use   MeSH
• Drug Therapy, Combination MeSH
• Brain parasitology   MeSH
• Mice MeSH
• Specific Pathogen-Free Organisms MeSH
• Pyrimethamine administration & dosage   therapeutic use   MeSH
• Robenidine administration & dosage   therapeutic use   MeSH
• Drug Administration Schedule MeSH
• Sulfadoxine administration & dosage   therapeutic use   MeSH
• Toxoplasmosis, Animal drug therapy   MeSH
• Animals MeSH
• Check Tag
• Mice MeSH
• Female MeSH
• Animals MeSH
• Publication type
• Journal Article MeSH
• Names of Substances
• Guanidines MeSH
• Pyrimethamine MeSH
• Robenidine MeSH
• Sulfadoxine MeSH